Evofem Biosciences, Inc. (EVFM)
OTCMKTS: EVFM · Delayed Price · USD
0.0105
+0.0005 (5.00%)
Jul 19, 2024, 3:59 PM EDT - Market closed
Evofem Biosciences Revenue
Evofem Biosciences had revenue of $16.01M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $3.60M. In the year 2023, Evofem Biosciences had annual revenue of $18.22M with 8.20% growth.
Revenue (ttm)
$16.01M
Revenue Growth
-12.95%
P/S Ratio
0.04
Revenue / Employee
$421,368
Employees
38
Market Cap
651.63K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
Dec 31, 2020 | 446.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 100.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Eli Lilly | 35.93B |
EVFM News
- 7 days ago - Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC - PRNewsWire
- 25 days ago - Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare - PRNewsWire
- 5 weeks ago - Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter - PRNewsWire
- 2 months ago - Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PRNewsWire
- 3 months ago - Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO - PRNewsWire
- 4 months ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 4 months ago - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy - PRNewsWire
- 6 months ago - Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PRNewsWire